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CANNABIS RELATED PSYCHIATRIC SYNDROMES: 
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Association between cannabis use and various psychiatric syndromes does exist, but their nature 
remains elusive. Cannabis intoxication, 'cannabis psychosis' and certain other conditions related with 
cannabis use like flashbacks and prolonged depersonalization are discussed in this paper. The 
controversial nature of the cannabis - schizophrenia link is noted, and various methodological issues 
in clinical cannabis research are highlighted. 
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INTRODUCTION 
Used in the Vedic era in India (Andrews & 
Vinkenoog, 1967) and recently identified in Egyp-
tian and Peruvian mummies (Parsche et al, 1993), 
cannabis is certainly not a new drug. Basic biologi-
cal research in cannabis and its psychoactive com-
ponents - the cannabinoids (Mechoulam, 1970) has 
made great strides in the past 30 years, from isolation 
of delta-9-tetrahydrocannabinol or simply THC 
(Gaoni '& Mechoulam, 1964), to molecular charac-
terization and anatomical localization of can-
nabinoid receptors in the brain (Matsuda et al, 1990; 
Herkenham et al, 1990) as well as in peripheral 
tissues (Munro et al, 1993). The latest excitement 
surrounds the discovery of an endogenous ligand for 
tbecannabinoid receptor, named'anandamide' from 
the Sanskritword 'ananda' or bliss (Devane et al, 
1992). 
Despite all these recent advances in the 
biomolecular research in cannabis, considerable 
controversy still rages around the clinical delinea-
tion of adverse psychological effects of cannabis or 
the cannabis related psychiatric syndromes 
(Negrete, 1988; Basu, 1992; Mathers & Ghodse, 
1992; Thomas, 1993). This is in spite of the fact that 
psychiatric effects of cannabis have been docu-
mented for more than one and a half centuries now 
(O'Shaughnessy, 1838-40; Moreaude Tours, 1845). 
Cannabis is probably the only drug that has been the 
focus of more than half a dozen national level en-
quiries in different countries over the last century, 
e.g., India (Indian Hemp Drugs Commission of In-
quiry into the Nonmedical use of Drug, 1972), etc. 
Any clear-out consensus is, however, yet to emerge. 
This provides the backdrop for this selective review 
and current status. 
OFFICIAL NOSOLOGICAL SYSTEMS 
The existing nosological uncertainly is reflected 
in both the official American (DSM m & III-R, 
American Psychiatric Association 1980 and 1987, 
respectively) as well as International (ICD-9 & 10, 
World Health Organization, 1978 and 1992, respec-
tively) classification systems. In the ensuing discus-
sion, the variously described syndromes of abuse, 
harmful use, dependence and withdrawal will not be 
reviewed. 
In both DSM-in and III-R, under the section 
heading 'substance induced organic mental 
disorders' there are two categories specifically con-
cerned with cannabis: cannabis intoxication and 
cannabis delusional disorder. While there is no con-
troversy regarding the former (with very minor 
changes in the revised edition), the texts explicitly 
state that the existence of the latter category is con-
troversial. It required the following criteria to be 
fulfilled in DSM III: A. Recent use of cannabis; B. 
An organic delusional syndrome within two hours 
of cannabis use; C. Duration of the syndrome not 
more than six hours following cessation of use; D. 
Not due to any other disorder. In DSM III-R, how-
ever, the duration criterion was dropped, and onset 
of the syndrome after cannabis use was relaxed from 
'two hours' to 'shortly'. 
While the American system was striving to be 
specific, the International system was broad and 
non-specific. The ICD-9 accommodated cannabis 
and other drugs (drug-induced psychosis with 
paranoid/hallucinatory features: code 292) and even 
other etiological factors (transient organic psychotic 
state: code 293). Further details related to cannabis 
were not provided. 
ICD-10 
This takes a much wider approach. Nine groups 
of psychoactive substances are covered under the 
heading Fl: Mental and Behavioral disorders due to 
Psychoactive substance use, the' Disorders resulting 
from use of cannabinoids' featuring as code F 12. 
Each of these 9 classes of substances may potentially 
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produce 10 types of clinical conditions, to be coded 
as 4th and 5th character codes. These include: 1) 
acute intoxication, 2) harmful use, 3) dependence 
syndrome, 4) withdrawal state, 5) withdrawal state 
with delirium, 6) psychotic disorder, 7) amnesic 
syndrome, 8) residual and late-onset psychotic dis-
order, 9) others, and 10) unspecified clinical condi-
tions. 
Many of these again have multiple sub-
categories. The approach has the empirical ad-
vantage of retaining more information than DSM 
III-R approach of specifying clinical conditions due 
to particular groups of drugs. For example, an acute-
onset psychosis after recent use of cannabis with 
predominantly polymorphic picture cannot be satis-
factorily coded in DSM III-R, but in ICD-10 this will 
be coded as F12.53, i.e., Disorders resulting from 
use of cannabinoids, psychotic disorder, 
predominantly polymorphic. However, the disad-
vantage of this approach is that while ensuring a 
broader coverage of syndromes, specificity is lost -
any substance can potentially produce almost any 
psychiatric disorder. In summary, the DSM ap-
proach is more specific but not exhaustive, whereas 
the ICD approach is more exhaustive but with a 
com prom ise on specificity, This nosological issue is 
still far from satisfactory. 
With this background, let us examine a widely 
use 'classification' of cannabis related psychiatric 
syndromes (Negrete, 1973). This teases out certain 
specific psychiatric conditions out of the various 
adverse psychological effects of cannabis, in terms 
of symptomatology, pattern of cannabis use, and 
duration of the illness. These are: 
1. Severe cannabis intoxication 
2. Pathological cannabis intoxication 
3. Acute cannabis psychosis 
4. Subacute and chronic cannabis psychosis 
5. Residual conditions such as amotivational 
syndrome, "echo" or flashback" phenomenon, and 
persistent depersonalization. 
THE INTOXICATION SYNDROMES 
Severe cannabis intoxication: 
There is probably the least controversy here 
(Tart, 1970; Weil, 1970). After consuming a large 
quantity of cannabis, the usual pleasurable effects of 
cannabis may be intensified to the extent of being 
unpleasant. In addition, one may have clouding of 
consciousness, disorientation, depersonalization 
and derealization, paranoid ideation, gross sensory 
distortion and deception in any sensory modality 
including visual and auditory hallucinations and 
transient cerebellar or pyramidal / extrapyramidal 
signs. Here the onset is sudden, closely following the 
cannabis consumption (faster when smoked), and 
duration is only a few hours. It is a dose related 
phenomenon, though the exact intensity and dura-
tion of the symptoms would depend upon charac-
teristics of the agent (i.e., the cannabis preparation 
and its potency), the host (e.g., the mental set of the 
subject and his past experiences with cannabis) and 
the environment (i.e., the setting in which cannabis 
is taken). Many symptoms have recently been ex-
plained on the basis of cannabinoid receptor 
localization patterns in the brain (Herkenham et al, 
1990). 
Pathological intoxication: 
This has a similar clinical picture; the onset and 
duration being similar to that of severe cannabis 
intoxication, except for the fact that it is precipitated 
by an average, usual or low dose of cannabis. These 
terms qualify with reference to the particular user in 
question. States are also more often characterized by 
panic attacks, persecutory ideation, or acute depres-
sive reaction. The affective component in the clini-
cal picture is usually more prominent than the 
cognitive component. According to Negrete (1973), 
personality faaors, expectations and setting play 
important roles in the genesis of this disorder. How-
ever, because of operational difficulties in deciding 
between a 'large' and a 'small' dose, it is generally 
not a nosological category, except in ICD-10 where 
it appears as a fifth character subcategory under 
'acute intoxication' (F 12.07) and then "applies only 
to alcohol", not cannabis (WHO, 1992). 
THE "CANNABIS PSYCHOSIS" SYNDROMES 
One of the most heated arguments in the recent 
ongoing cannabis debated concerns the existence of 
a distinct nosologic entity which could be rightfully 
identified as'cannabis psychosis'. Although alluded 
to in the Indian Hemp Drugs Commission Report in 
1893-94, the first scientific communication regard-
ing the 'Indian Hemp Insanity* came from Ewens in 
1904. In fact, this condition was earlier thought to 
be "peculiar to the country", i.e., India (Dhunjibhoy, 
1930). Though later reported from various parts of 
the world, such as India (Varma, 1972; Thacore, 
1973; Chopra & Smith, 1974; Thacore & Shukla, 
1976; Chaudhury & Augustine, 1989) Pakistan 
(Chaudhry et al, 1991), African countries (Rottan-
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burg et aL 1982; Solomons et al, 1989; Imade & 
Ebie, 1991), Scandinavian countries (Bernahardson 
&Gunne, 1972; Palssonetal, 1982;Tunving, 1985), 
West Indies (Knight, 1976), the United Kingdom 
(Carney et al, 1984; Drummond, 1986; Onyango, 
1986) and the United States of America (Kolansky 
& Moore, 1971), the clinical validity and nosologic 
status of these cannabis psychoses syndromes 
remain unclear. 
Ghodse (1986) reviewed this area recently and 
arrived at the conclusion that it is quite certain that 
cannabis is capable of causing an acute toxic 
psychosis with confusion, disorientation, delusions, 
hallucinations and affective symptoms. This seems 
to be does-related, with a predictably brief and self-
limiting course of hours of hours to a few days after 
cannabis use is stopped. 
The evidence for a longer-lasting "functional 
psychosis" is rather weak, though not entirely ruled 
out. This category, characterized by paranoid, hal-
lucinatory and / or hypomanic features with relative-
ly clear sensorium, appearing in long-term heavy 
cannabis users and lasting for weeks to months, has 
been subject to the greatest controversy (Negrete, 
1988). An alternative view is that the basic disorder 
is an independent functional psychosis, especially 
schizophrenia or affective disorder, which is 
precipitated, aggravated or modified by the use of 
cannabis; this view seems to be favored currently 
(Mathers & Ghodse, 1992; Thomas, 1993 b; Saxena, 
1993). However, protagonists of the "functional can-
nabis psychosis" maintain that this is an independent 
nosological entity in its own right. They support 
their argument by the following facts: these patients 
usually do not have evidence for latent or overt 
psychosis prior to the cannabis use, 2) some clinical 
features tend to differentiate the two groups of can-
nabis psychosis and schizophrenia or affective dis-
order, 3) the psychotic illness almost invariably 
subsides after stoppage of cannabis use, 4) often 
there is a psychotic relapse when cannabis use is 
resumed, and finally, 5) cannabinoids and their ac-
tive metabolites may indeed last in the body for a 
month or more, documented by sophisticated 
laboratory techniques (Bernhardson & Gunne, 
1972; Tunving, 1985; Drummond, 1986; Onyango, 
1986). 
In India, a recently conducted clinical survey 
found non-specific psychosis and persecutory 
delusions in nearly half of 170 patient of cannabis 
abuse attending a deaddiction clinic and that "the 
cross-sectional profile of psychiatric morbidity ap-
peared to be different from schizophrenia and affec-
tive disorders" (Ramachandran et al, 1989). A case 
control study done by us (unpublished) on the clini-
cal features, course and outcome of "cannabis 
psychosis" vis-a-vis acute schizophrenic episode 
also warrants similar conclusions. The issue how-
ever, is far from settled because of the many 
methodological problems (discussed later). 
THE "AMOTIVATIONAL" SYNDROME 
Described first by McGlothlin & West (1986), 
this is defined as "a set of symptoms including 
apathy, ineffectiveness and non-productiveness 
considered to reflect a deficit in general motivation... 
resulting from the use of certain drugs" (Commis-
sion of Inquiry into the Non-medical Use of Drugs, 
1972). Many regular cannabis users were observed 
to become apathetic, lose drive and sense of purpose, 
indulge in idle day dreaming and evade activities 
which required sustained goal directed effort. After 
initial debate, with opposite views coming from 
different countries like Greece (Mellinger et aL 
1976), India (Chopra & Jandu, 1976),Canada 
(Campbell, 1976) and West Indies (Comitas, 1976), 
it is generally held now that if cannabis users do 
differ from non-users with respect to the above 
mentioned features, the differences may simply arise 
from dissimilarities in their social, family and 
psychological backgrounds, and that such a state 
should not be thought of as a separate clinical entity 
(Granville-Grossman,1979; Negrete, 1988). 
OTHER PSYCHIATRIC SYNDROMES RELATED 
TO CANNABIS 
Echo or Flashback phenomenon: 
First reported by Keeler et al (1988), these consist 
of re-experiencing the various perceptual and cog-
nitive effects of the drug at a later date while not 
under its influence any more. Although better known 
with LSD, several reports of cannabis flashback 
have also been published (Bialos, 1970; Stanton & 
Bardoni, 1972; Chopra & Smith, 1974; Keshavan & 
Lishman, 1986). The newer understanding of the 
pharmacokinetics of cannabinoids puts in doubt the 
existence of truly drug-less flashback reactions. It 
seems quite possible that such experiences may be 
the result of a continuous or intermittent release of 
psychoactive com ponent from adipose tissues where 
they are stored during periods of active usage 
(Thomas, 1993). The flashbacks may be indeed 
pleasant to some users (Stanton et al, 1976). 
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Persbtent depersonalization: 
There are only a few case reports where cannabis 
use led to a state of prolonged depersonalization 
(Szymansky, 1981; Keshavan & Lishman, 1986). 
The mechanism is unclear at present, though it may 
again be related to the long elimination half-life of 
active cannabinoid metabolites, or may be due to 
residual neurotoxicity of cannabinoid products. 
Cannabis and schizophrenia: 
Both clinical (Schneier & Siris, 1987) as well as 
community (Bland et al, 1987) studies found the 
lifetime prevalence of cannabis use to be significant-
ly higher among schizophrenics than in comparison 
groups, including other psychiatric disorders 
(Weller et al, 1988). Also, many schizophrenics 
seem to prefer cannabis to other drugs except tobac-
co (Knudsen & Vilma, 1984; Schneier & Siris, 
1987). A doubled risk of psychotic experiences was 
found in daily users of marijuana in a large scale 
community survey (Tien & Anthony, 1990), though 
not universally agreed upon (Thornicroft, 1990). 
Finally, it is accepted that cannabis use alters 
schizophrenic course (Treffert, 1978), by either in-
creasing positive symptoms (Negrete et al, 1986) or 
decreasing negative symptoms, especially alogia 
(Peralta & Cuesta, 1992). 
The true nature of this apparent association be-
tween cannabis use and schizophrenia, however, 
remains controversial. Large scale register based 
Swedish studies indicate use (and especially heavy 
use) of cannabis to be an independent risk factor for 
later development of schizophrenia and not the other 
way round (Andreasson et al, 1987 & 1989; Al-
lebeck et al, 1993). Although theoretically tenable 
by the property of cannabis to increase brain 
dopamine levels (Patel et al, 1985) or to amplify 
pre-existing trend of deviant behavior (Foltin et al, 
1987), this view is not endorsed by others (Johnson 
et al, 1988; Negrete, 1989; Mathers & Ghodse, 
1992), who consider that other confounding vari-
ables (e.g., other drug use, premorbid personality, 
background sociocultural and ethnic / environmen-
tal factors) have to be considered before drawing 
such a causal conclusion. 
METHODOLOGICAL ISSUES IN CUNICAL 
CANNABIS RESEARCH 
1) Cannabis is a pharmacologically "dirty" drug 
(Ashton, 1987). It contains so may active com-
pounds, each with different pharmacokinetics and 
detectability, wherein it becomes very difficult to 
study the effects of cannabis in relation to any one 
compound. Also, the concentrations of these vary 
from one cannabis preparation to another. 
2) Cannabis is rarely taken in isolation. Quite 
often other drugs or alcohol are used concomitantly, 
agents that may be etiologically related to the target 
syndrome studied. 
3) Lack of proper sampling often makes inter-
pretation of studies difficult. Most samples are 
'samples of convenience' rather than 'samples of 
choice'. 
4) Earlier studies often did not employ a com-
parison group. Later studies, although employing 
various control groups, have often employed inap-
propriate controls. This has been a consistent limita-
tion in many studies regarding amotivation 
syndrome, cannabis psychosis and cannabis induced 
organic brain damage. 
5) Most studies are retrospective in design. Not 
that these are totally non-contributory, but the inter-
pretation calls for caution. 
6) Another methodological hurdle is the un-
reliability of reported drug use data, especially can-
nabis. Chances of retrospective falsification are 
high. Also, in India, people often use the terms 
'ganja', 'bhang','charas\ 'sulfa', and 'sukha' incor-
rectly and interchangeably. This makes quantifica-
tion difficult. 
7) Application of standardized instruments is 
another problem, especially in the study of cannabis 
psychosis. Since the form and content of 
psychopathology are often culturally influenced, 
proper choice of a psychopathology rating scale 
becomes important across cultures. 
8) Inferences drawn from different theoretical 
frameworks differ themselves. Thus, researchers 
who consider schizophrenia to be the basic disorder 
and cannabis to influence its course, will study the 
role of cannabis in schizophrenia. Another group of 
researchers who incorporate the concept of an inde-
pendent cannabis psychosis in their theoretical 
framework will probably consider the same data to 
infer that cannabis does cause cannabis psychosis. 
For example, the same study by Rottanburg et al 
(1982) has been cited by some authors to support the 
notion of 'functional cannabis psychosis' (Ghodse, 
1988) and by other authors to show the influence of 
cannabis on schizophrenic symptomatology (Peralta 
& Guesta, 1992), whereas Rottanburg et al's original 
paper was sim ply on' cannabis-associated psychosis 
with hypomanic features'. 
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9) The pathoplastic influence of sociocultural 
factors is another important issue, especially in dis-
cussions on the amotivational syndrome and can-
nabis psychosis. 
10) Finally, it has been commented that a truly 
'unbiased' researcher in the cannabis issue is only 
rarely found. With cannabis, personal and social 
attitudes and norms often dominate in the interpreta-
tion of drug effects. For example, cannabis effects 
subjectively considered 'psychedelic' or 'peak' may 
be defined as 'psychotic' by others. Feelings of 
increased sensitivity to humor may be alternately 
viewed as 'loquacious euphoria' by others (Com-
mission of Inquiry with the Non-medical use of 
Drugs, 1972). 
CONCLUSION AND SUGGESTIONS FOR 
FURTHER RESEARCH 
Are we much wiser than when we began? Con-
sidering the numerous methodological obstacles in 
research in the field, the answer is uncertain. This, 
of course, should not mean that further research in 
this area would be futile. Equipped with more 
sophisticated laboratory techniques, more consen-
sually validated instruments, an ever increasing 
treasure of knowledge regarding the existence and 
delineation of certain cannabis related psychiatric 
syndromes, and finally, with the much more exhaus-
tive list of cannabis related clinical conditions 
nosologically agreed to by the ICD-10, probably the 
time is set for much more scientific as well as 
culturally valid research in this area than ever before. 
In India, a particular section of the lower 
socioeconomic strata has long been noted for 
regular, customary and heavy use of cannabis. This 
section is remarkable for the consistency of cannabis 
use, "consistency" being qualified not only in terms 
of chronicity and heaviness of use, but also in terms 
of use of a particular preparation (e.g., ganja or 
bhang), situation of use (e.g., in "social" gatherings 
in a temple), time of use (e.g., towards the evening 
after the day's work is over), and relative absence of 
other substance use (except tobacco and occasional-
ly alcohol). This sizeable section of chronic heavy 
cannabis users has surprisingly evaded rigorous 
scientific attention so far. Carefully designed 
prospective longitudinal studies (preferably multi-
centric) employing this section as a community 
cohort should yield very useful information about 
epidemiology, biopsychosocialaetiology, nosology, 
course and outcome of various cannabis related 
psychiatric syndromes. This may indeed be a unique 
Indian contribution to the relevant world literature. 
Given, however, the considerable practical dif-
ficulties inherent in conducting such community 
level studies, even clinic based prospective cohort 
studies may partly help. Though not very useful for 
epidemiology and aetiology, these may shed further 
light on other aspects, especially on the current issue 
of cannabis abuse and course of schizophrenia, as 
demonstrated by a recent well designed study from 
the Netherlands (Linszen et al, 1994) and another 
from Spain (Martinez-Arivalo, 1994). Both these 
studies showed that cannabis abuse was a specific 
risk factor for psychotic relapse over one year of 
prospective follow-up. Similar studies from India 
are feasible, potentially useful, hence warranted. 
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